News Image

Exploring the Growth Potential of NASDAQ:HALO as It Nears a Breakout.

By Mill Chart

Last update: Apr 30, 2024

Exploring Growth Potential: HALOZYME THERAPEUTICS INC (NASDAQ:HALO) and Its Base Formation. Growth investors seek promising revenue and EPS growth, and HALOZYME THERAPEUTICS INC has come under our scrutiny for potential growth investing. While it's crucial to do your own research, we've detected HALOZYME THERAPEUTICS INC on our screen for growth with base formation, suggesting it merits a closer look.

What does the Growth looks like for NASDAQ:HALO

ChartMill employs its own Growth Rating system for all stocks. This score, ranging from 0 to 10, is derived by evaluating different growth factors, such as EPS and revenue growth, taking into account both past performance and future projections. NASDAQ:HALO has earned a 9 for growth:

  • HALO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.23%, which is quite impressive.
  • HALO shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 45.64% yearly.
  • HALO shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.59%.
  • Measured over the past years, HALO shows a very strong growth in Revenue. The Revenue has been growing by 40.42% on average per year.
  • HALO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.73% yearly.
  • The Revenue is expected to grow by 11.91% on average over the next years. This is quite good.

Understanding NASDAQ:HALO's Health Score

ChartMill employs its own Health Rating for stock assessment. This rating, ranging from 0 to 10, is calculated by examining various liquidity and solvency ratios. In the case of NASDAQ:HALO, the assigned 7 reflects its health status:

  • An Altman-Z score of 3.43 indicates that HALO is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of HALO (3.43) is better than 76.28% of its industry peers.
  • HALO has a Debt to FCF ratio of 4.02. This is amongst the best in the industry. HALO outperforms 95.05% of its industry peers.
  • HALO has a Current Ratio of 6.64. This indicates that HALO is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 6.64, HALO is in the better half of the industry, outperforming 66.55% of the companies in the same industry.
  • HALO has a Quick Ratio of 5.50. This indicates that HALO is financially healthy and has no problem in meeting its short term obligations.

Looking at the Profitability

Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:HALO has achieved a 7:

  • The Return On Assets of HALO (16.25%) is better than 98.98% of its industry peers.
  • The Return On Equity of HALO (335.99%) is better than 100.00% of its industry peers.
  • HALO has a Return On Invested Capital of 17.00%. This is amongst the best in the industry. HALO outperforms 98.46% of its industry peers.
  • HALO had an Average Return On Invested Capital over the past 3 years of 17.78%. This is above the industry average of 13.85%.
  • HALO has a Profit Margin of 33.96%. This is amongst the best in the industry. HALO outperforms 99.15% of its industry peers.
  • HALO has a Operating Margin of 41.02%. This is amongst the best in the industry. HALO outperforms 99.49% of its industry peers.
  • The Gross Margin of HALO (76.82%) is better than 86.35% of its industry peers.

Looking at the Setup

ChartMill also assign a Setup Rating to every stock. With this score it is determined to what extend the stock has been trading in a range in the recent days and weeks. This score also ranges from 0 to 10 and is updated daily. The setup score evaluates various short term technical indicators. NASDAQ:HALO scores a 7 out of 10:

Although the technical rating is only medium, HALO does present a nice setup opportunity. We see reduced volatility while prices have been consolidating in the most recent period. There is a support zone below the current price at 38.73, a Stop Loss order could be placed below this zone.

Every day, new Strong Growth stocks can be found on ChartMill in our Strong Growth screener.

Check the latest full fundamental report of HALO for a complete fundamental analysis.

Check the latest full technical report of HALO for a complete technical analysis.

Keep in mind

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (5/20/2024, 7:00:01 PM)

After market: 44.97 0 (0%)

44.97

+0.26 (+0.58%)

HALO News

News Image4 days ago - Market News VideoHALO July 19th Options Begin Trading
News Image4 days ago - Investor's Business DailyHalozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating

On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier.

News Image6 days ago - Investor's Business DailyCatalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating

On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79.

News Image7 days ago - ChartmillWhile growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.

Investors seeking growth at a reasonable cost should explore NASDAQ:HALO.

News Image12 days ago - USA News GroupBiotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

/CNW/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the...

News Image12 days ago - USA News GroupBiotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

/PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of...

News Image12 days ago - InvestorPlaceThe 3 Best Biotech Stocks to Buy in May 2024

If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May.

News Image13 days ago - Halozyme Therapeutics, Inc.Halozyme to Participate in Upcoming Investor Conferences

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present...

News Image13 days ago - ChartmillWhen you look at NASDAQ:HALO, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

When you look at HALOZYME THERAPEUTICS INC (NASDAQ:HALO), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.

News Image13 days ago - InvestorPlaceHALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024

HALO stock results show that Halozyme Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

News Image13 days ago - BusinessInsiderHALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Halozyme Therapeutics (NASDAQ:HALO) just reported results for the first quarter...

News Image13 days ago - Halozyme Therapeutics, Inc.HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS

Revenue Increased 21% YOY to $196 million; Net Income of $77 million; Adjusted EBITDA of $116 million; GAAP Diluted EPS of $0.60 and Non-GAAP Diluted EPS of $0....

HALO Links
Follow us for more